https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2007-04-04 13:22:312016-11-28 13:47:13SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at AACR
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2007-04-03 13:23:032016-11-28 13:47:39Nipent® Acquisition by Hospira is Complete
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2007-03-02 13:24:122016-11-28 13:48:31SuperGen to Present Discovery Platform and Pipeline Update at Analyst and Investor Day
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2007-03-01 13:24:452016-11-28 13:48:53SuperGen to Release 2006 Fourth Quarter and Year-End Financial Results March 14
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2007-03-01 12:25:142016-11-28 13:49:16SuperGen to Webcast March 2 Analysts and Investor Day
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2006-12-04 13:49:342016-11-28 13:50:11Astex Therapeutics Appoints John Aston Chief Financial Officer
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2006-11-10 13:50:502016-11-28 13:51:11SuperGen Presents Preclinical Data on Selected Lead Kinase Compounds and DNA Methylation Inhibitor at EORTC
https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg00webadminhttps://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svgwebadmin2006-11-09 13:51:152016-11-28 13:51:41SuperGen Presents Preclinical Data at EORTC On MP-529, a Selective Kinase Inhibitor and CLIMB™ Process in Drug Discovery and Design
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
